



P K R JAIN HEALTHCARE INSTITUTE

NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

☎ 0171-2532620, 8222896961

✉ pkrjainhealthcare@gmail.com

NAME : Mr. RAJNEESH KUMAR

AGE/ GENDER : 43 YRS/MALE

COLLECTED BY :

REFERRED BY :

BARCODE NO. : 12505659

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

PATIENT ID : 1672610

REG. NO./LAB NO. : 122411150009

REGISTRATION DATE : 15/Nov/2024 10:13 AM

COLLECTION DATE : 15/Nov/2024 10:56AM

REPORTING DATE : 15/Nov/2024 11:37AM

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

CLINICAL CHEMISTRY/BIOCHEMISTRY

LIPID PROFILE : BASIC

CHOLESTEROL TOTAL: SERUM
by CHOLESTEROL OXIDASE PAP

171.85

mg/dL

OPTIMAL: < 200.0
BORDERLINE HIGH: 200.0 - 239.0
HIGH CHOLESTEROL: > OR = 240.0

TRIGLYCERIDES: SERUM
by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)

189.53^H

mg/dL

OPTIMAL: < 150.0
BORDERLINE HIGH: 150.0 - 199.0

HDL CHOLESTEROL (DIRECT): SERUM
by SELECTIVE INHIBITION

40.14

mg/dL

HIGH: 200.0 - 499.0
VERY HIGH: > OR = 500.0
LOW HDL: < 30.0
BORDERLINE HIGH HDL: 30.0 - 60.0

LDL CHOLESTEROL: SERUM
by CALCULATED, SPECTROPHOTOMETRY

93.8

mg/dL

HIGH HDL: > OR = 60.0
OPTIMAL: < 100.0
ABOVE OPTIMAL: 100.0 - 129.0
BORDERLINE HIGH: 130.0 - 159.0

NON HDL CHOLESTEROL: SERUM
by CALCULATED, SPECTROPHOTOMETRY

131.71^H

mg/dL

HIGH: 160.0 - 189.0
VERY HIGH: > OR = 190.0
OPTIMAL: < 130.0
ABOVE OPTIMAL: 130.0 - 159.0
BORDERLINE HIGH: 160.0 - 189.0

VLDL CHOLESTEROL: SERUM
by CALCULATED, SPECTROPHOTOMETRY

37.91

mg/dL

HIGH: 190.0 - 219.0
VERY HIGH: > OR = 220.0
0.00 - 45.00

TOTAL LIPIDS: SERUM
by CALCULATED, SPECTROPHOTOMETRY

533.23

mg/dL

350.00 - 700.00


CHOLESTEROL/HDL RATIO: SERUM
by CALCULATED, SPECTROPHOTOMETRY


4.28

RATIO

LOW RISK: 3.30 - 4.40
AVERAGE RISK: 4.50 - 7.0




DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY)





P K R JAIN HEALTHCARE INSTITUTE

NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

☎ 0171-2532620, 8222896961 ✉ pkrjainhealthcare@gmail.com

NAME : Mr. RAJNEESH KUMAR
AGE/ GENDER : 43 YRS/MALE
COLLECTED BY :
REFERRED BY :
BARCODE NO. : 12505659
CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE
CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

PATIENT ID : 1672610
REG. NO./LAB NO. : 122411150009
REGISTRATION DATE : 15/Nov/2024 10:13 AM
COLLECTION DATE : 15/Nov/2024 10:56AM
REPORTING DATE : 15/Nov/2024 11:37AM

Test Name	Value	Unit	Biological Reference interval
LDL/HDL RATIO: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	2.34	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0
TRIGLYCERIDES/HDL RATIO: SERUM <i>by CALCULATED, SPECTROPHOTOMETRY</i>	4.72	RATIO	3.00 - 5.00


INTERPRETATION:

1. Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.
2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogenic lipoproteins such as LDL, VLDL, IDL, Lp(a), Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL & Non HDL.
5. Additional testing for Apolipoprotein B, hsCRP, Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

*** End Of Report ***




DR. VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)


DR. YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY)

